Concentras Parent Research and Development Expenses 2022-2025 | CON

Concentras Parent research and development expenses from 2022 to 2025. Research and development expenses can be defined as an expense arising from studies and product development processes.

Concentras Parent Research and Development Expenses 2022-2025 | CON

Concentras Parent research and development expenses from 2022 to 2025. Research and development expenses can be defined as an expense arising from studies and product development processes.
Related Stocks
Company NameMarket
Cap
Danaher (DHR)$147.1B
CVS Health (CVS)$76.8B
Elevance Health (ELV)$65.1B
Cencora (COR)$56.3B
DiDi Global (DIDIY)$25.7B
Labcorp Holdings (LH)$22.2B
Natera (NTRA)$19B
BioMerieux (BMXMF)$17.7B
EUROFINS SCIENT (ERFSF)$15.9B
ICON (ICLR)$15.1B
CochLear (CHEOY)$13.4B
Solventum (SOLV)$12.9B
Medpace Holdings (MEDP)$12.6B
Revvity (RVTY)$12.2B
Viatris (VTRS)$11B
Avantor (AVTR)$9.7B
Sonic Healthcare (SKHHY)$9.1B
Charles River Laboratories (CRL)$8.7B
HealthEquity (HQY)$8.3B
Caris Life Sciences,�Inc (CAI)$7.5B
Amplifon S.p.A (AMFPF)$5.4B
Bausch + Lomb (BLCO)$5.1B
BrightSpring Health Services (BTSG)$3.6B
Sotera Health (SHC)$3.5B
Surgery Partners (SGRY)$2.7B
Organon (OGN)$2.7B
Alignment Healthcare (ALHC)$2.3B
GeneDx Holdings (WGS)$2.3B
Progyny (PGNY)$2B
GoodRx Holdings (GDRX)$1.8B